A high-throughput screen of pharmacologically active compounds for inhibitors of UHRF1 reveals epigenetic activity of anthracycline derivative chemotherapeutic drugs
Hugh Giovinazzo(Sidney Kimmel Comprehensive Cancer Center), Srinivasan Yegnasubramanian(Johns Hopkins University)
Cited by 18
Related Papers
Metabolic programs define dysfunctional immune responses in severe COVID-19 patients
|Cell Reports|2021|135
A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target
|Journal of Clinical Investigation|2020|133
Pervasive promoter hypermethylation of silenced TERT alleles in human cancers
|Cellular Oncology|2020|25